This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma

Stocks in this article: ETRM ABIO KERX VVUS FMS AMRN

BOSTON (TheStreet) -- Before I open this week's Biotech Stock Mailbag, I want to remind everyone to vote for the Best Biotech CEO of 2013 award.

This year's nominees are Francois Naper of NPS Pharma (NPSP), Tony Coles of Onyx Pharma, Bristol-Myer Squibb's  (BMY) Lamberto Andreotti, Bob Hugin of Celgene  (CELG) and Ligand Pharma's  (LGND) John Higgins.

Vote! Twice, if necessary. This year's nominees for Worst Biotech CEO of 2013 will be unveiled on Monday.

I also want to thank David Sable and David Shaywitz for my new nickname -- the Colonel Jessep of biotech and drug stocks. I will try to live up to the new moniker below.

Arthur H. asks:

Adam, have you looked at the new Enteromedics  (ETRM) data issued this week? I'd like to know if you think this will lead to an FDA approval? I know you don't like the obesity pills but Enteromedics device could be a better alternative for people. I'd appreciate hearing what you have to say. Thanks.

Enteromedics is a complicated story but I'm going to try to simplify things, starting with a question:

How much weight did obese patients lose after being implanted with the Enteromedics VBLOC Therapy device?

Enteromedics announced results from the 12-month VBLOC phase III study last February (the study failed) but numerical or even percentage weight loss by patients was not disclosed. This week, Enteromedics announced an 18-month update from the phase III study with only a brief -- and cryptic -- disclosure about actual weight loss.

I found it odd that a company seeking FDA approval for a surgically implanted weight-loss pacemaker would be so coy about disclosing weight loss data, so I asked Enteromedics CFO Greg Lea. Here are the weight-loss data from the VLBOC "Recharge" study:

Patients with active VBLOC Therapy devices lost an average of 9.2% (23 pounds) of their body weight after one year. Patients with implanted devices that were not turned on -- the control arm of the study -- loss 6% (15 pounds) over one year.

This means average VBLOC Therapy weight loss was 3% (8 pounds) adjusted for the control.

Is 8 pounds of weight loss over one year clinically meaningful? That's a question FDA must decide but seems dicey to me given the VBLOC pacemaker must be surgically implanted and treatment requires patients to wear a control belt around their waist for 9-12 hours per day.

Enteromedics' Lea argues that the control arm from the study should be disregarded because patients were surgically implanted with an inactive device. These are not real "placebo" patients, he says, so it's more meaningful to look at the weight loss derived from active VBLOC Therapy on its own.

Fine. A year's worth of VBLOC Therapy resulted in an average 9% weight loss, which is equivalent to the weight loss patients get with a year's worth of Vivus'  (VVUS) Qsymia, minus the surgery, the belt, and the hours upon hours of electrical zaps to your vagus nerve.

I don't find Lea's argument persuasive, but again, it's the FDA's call.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs